Plain-English translation of NCT07854782 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help treat a common liver disease where too much fat builds up in the liver. The medication works by blocking a protein that helps the liver store fat. Researchers want to find out if this treatment can reduce liver fat, inflammation, and scarring while being safe to use.
Right now, there are very few medications approved to treat this liver disease, and many people with fatty liver disease go on to develop serious liver damage. This trial is testing whether this medication could become a new treatment option to help prevent that progression.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication (at one of two dose levels) or a placebo (a pill with no active medicine) over the course of the trial. You would take your assigned treatment regularly and attend study visits where doctors will perform blood tests, liver ultrasound scans, and other measurements to track how the medication affects your liver health. The trial will monitor you for any side effects and measure changes in liver fat, inflammation, and scarring over time.
AI-generated summary from trial data · Nov 2, 2026 · Not medical advice
United States